Autophagy modulation with bioactive compounds represents a promising therapeutic strategy for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Neurodegenerative disorders are characterized by the accumulation of misfolded proteins and impaired cellular clearance mechanisms. Autophagy—a critical lysosome-dependent degradative pathway—maintains proteostasis and neuronal health, making it an attractive therapeutic target[1].
The autophagy-lysosome pathway is essential for cellular homeostasis. It involves the degradation of damaged organelles, protein aggregates, and intracellular pathogens through lysosomal fusion. There are three main types of autophagy:
Dysregulation of autophagy contributes to the pathogenesis of neurodegenerative diseases through accumulation of toxic protein aggregates like amyloid-beta, tau, and alpha-synuclein[1:1].
The autophagy process involves multiple protein complexes that orchestrate each stage of autophagosome formation and maturation[2]:
Initiation:
Nucleation:
Expansion:
Fusion and Degradation:
In neurodegenerative diseases, autophagy impairment occurs at multiple levels:
The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and metabolism. mTORC1 (mTOR complex 1) inhibits autophagy under nutrient-rich conditions by phosphorylating key autophagy proteins:
Rapamycin and its analogs (rapalogs) are mTOR inhibitors that induce autophagy by relieving mTORC1-mediated inhibition. However, complete mTOR inhibition can have adverse effects, driving interest in natural compounds that modulate autophagy through alternative mechanisms.
Elevation of intracellular cAMP can induce autophagy through Epac and activation of protein phosphatase 2A (PP2A), which dephosphorylates and activates the ULK1 complex.
Calcium influx through various channels can stimulate autophagy:
AMP-activated protein kinase (AMPK) senses energy deficiency and activates autophagy by:
Resveratrol is a natural polyphenol found in grapes, berries, and peanuts. It activates autophagy through multiple mechanisms:
Resveratrol promotes clearance of amyloid-beta and tau aggregates in cellular and animal models of Alzheimer's disease[7].
Curcumin, the primary active compound in turmeric, modulates autophagy through multiple interconnected pathways[8]:
Curcumin has shown particular promise in promoting alpha-synuclein clearance in Parkinson's disease models through enhanced macroautophagy and chaperone-mediated autophagy[9].
EGCG, the most abundant catechin in green tea, induces autophagy through multiple pathways[7:1]:
EGCG has demonstrated neuroprotective effects in multiple neurodegenerative disease models, with particular benefit in Alzheimer's disease by promoting clearance of amyloid-beta aggregates through autophagy enhancement[10].
Flavonoids represent a diverse class of polyphenolic compounds that modulate autophagy:
| Compound | Primary Target | Disease Relevance |
|---|---|---|
| Quercetin | AMPK, mTOR | AD, PD |
| Luteolin | AMPK, PI3K | AD, PD |
| Baicalein | mTOR, Beclin-1 | AD |
| Fisetin | AMPK, SIRT1 | AD, PD |
These additional bioactive compounds offer complementary mechanisms for autophagy modulation[11]:
Autophagy and neuroinflammation are intimately connected through reciprocal regulation[11:1]:
Autophagy modulation shows promise for Alzheimer's disease by promoting clearance of pathological proteins while addressing multiple aspects of AD pathogenesis[12]:
The autophagy-lysosome pathway is particularly important in neurons due to their post-mitotic nature and high metabolic demands. Autophagy decline with age may contribute to sporadic AD risk[13].
For Parkinson's disease, autophagy induction targets multiple pathological mechanisms[9:1]:
Autophagy modulators may benefit ALS through multiple mechanisms[6:1]:
A major challenge in developing autophagy-modulating therapies is achieving sufficient drug concentrations in the brain[14]:
Many natural compounds have poor BBB penetration due to their inherent physicochemical characteristics:
Multiple strategies are being explored to overcome BBB challenges:
Translating bioactive compound autophagy modulators from preclinical promise to clinical reality presents significant challenges[14:1]:
Pharmacokinetics:
Clinical Trial Design:
Autophagy exhibits dual roles in neurodegeneration—excessive or insufficient autophagy can be harmful. Context- and stage-specific modulation is essential for therapeutic success.
Combining autophagy inducers with other therapeutic approaches may enhance efficacy:
Identifying biomarkers for autophagy activity will help:
Singh AK, Kush A, Bhushan B, Dhanawat M, Sharma PK. Targeting Autophagy with Bioactive Compounds: Therapeutic Potential in Neurodegenerative Disorders. Current Neuropharmacology. 2026. ↩︎ ↩︎
Liu Q, Chen Y, Paul B, et al. Autophagy and mitophagy in neurodegeneration. J Neurochem. 2019. ↩︎
Lin TK, Chen SD, Chuang YC, et al. Autophagy and its role in neurodegeneration. Int J Mol Sci. 2018. ↩︎
Frake RA, Ricketts T, Menzies FM, et al. Autophagy and neurodegeneration. J Clin Invest. 2022. ↩︎
Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion. Nature. 2008. ↩︎
Comincini L, Girelli M, D'Urso A, et al. Autophagy and neurodegenerative diseases. Exp Neurol. 2017. ↩︎ ↩︎
Sawda M, Maher P, Manteiga A, et al. Resveratrol and neurodegenerative diseases. Mol Neurobiol. 2017. ↩︎ ↩︎
Rivera-Espinosa Y, Muriel P. Autophagy and related mechanisms. Pharmacol Res. 2015. ↩︎
Carrasco E, Blomgren K, Noureddine N. Autophagy as a target for neuroprotection. Neural Regen Res. 2019. ↩︎ ↩︎
Khandelwal PJ, Herman AM, Hoe HS, et al. Autophagy in Alzheimer's disease and Alzheimer's disease-like pathologies. Mol Neurobiol. 2016. ↩︎
Gupta MK, Woldeselassie Z, Belemkar S, et al. Autophagy and neuroinflammation. Adv Neurobiol. 2019. ↩︎ ↩︎
Li L, Wang Z, Wang L, et al. Autophagy and Alzheimer's disease: exploring the autophagic-lysosomal pathway in neurodegeneration. J Alzheimers Dis. 2018. ↩︎
Silva DF, Esteves AR, Cardoso SM. Autophagy in neurodegenerative diseases. Adv Exp Med Biol. 2018. ↩︎
Levenson CW, Larkin NR. Resveratrol and Alzheimer's disease: statistical evidence for a clinical trial. J Nutr Health Aging. 2014. ↩︎ ↩︎